{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'effect or pattern of response with anti-pegloticase Ab titers/types. This aim will be supported by analyses that compares', 'the treatment groups using two group t-tests and regression analyses that include the time of the sampling (an offset) to', 'adjust for any 12 or 24 week samples that may be taken earlier at the time of failure or dropout. Repeated measures', 'assessments using all Ab data (both data points: baseline and last observation) will be assessed using random effects in', 'PROC MIXED to assess the variability in response over time. Comparisons will be assessed using pre-specified contrasts.', 'Analyses of the sUA will be similarly assessed using PROC MIXED with random effects for participant. In addition,', 'addressing the secondary aim: b) determining the proportion of participants with sUA < 6 mg/dL through 24 weeks, and', \"Week 12 to Week 24; will be examined using Fisher's exact test. Continuous models estimating the areas under the\", 'dose-time curve with estimation based on using the trapezoidal rule will be constructed and adjusted for time under', 'study yielding an average sUA during the observation period. These areas under the curve will be compared using', 'similar linear models with an offset for the time under study. Exploratory analyses will assess association of covariates', 'within group areas under the curve; 2) Identify and characterize the pegloticase immune response by immunoglobulin', 'isotypes (IgG and IgM), specificities, and Ab titer.', 'These secondary outcome variables will be summarized using means with standard deviation, confidence intervals,', 'and/or median and interquartile ranges, dependent on their distribution and plots of their response alone and in', 'combination. Secondary endpoints will examine different definitions of sUA levels by plotting the initial values versus', 'change values on the unbiased outcome results and time weighted averages; and 3) Examine PROs using the NIH', 'supported Patient Reported Outcomes Measurement Information System (PROMIS) 57,58 and Gout Impact Scale (GIS) 59,60', 'instruments; these will use similar approaches of descriptive statistics, plots of PROs versus outcomes and correlations.', 'The PROs will be summarized by change over time using means, 95% confidence intervals and compared between', 'responder and non-responder status. We do not plan to control for the repeated testing using adjustments for multiple', 'comparisons since this is a feasibility trial and since statistical significance is not the goal as it would be in a pivotal trial.', 'The sample size is small and we see these secondary as well as primary analyses as descriptive. The p-values will be', 'calculated, but will take the totality of the evidence into account in the interpretation. We considered using hierarchical', 'testing such that each test would be done at the 0.05 level, but the low power argues that such could easily lead back to', 'not considering secondary endpoints.', '10.4.4 BASELINE DESCRIPTIVE STATISTICS', 'Intervention groups will be compared on baseline characteristics and will include the following.', 'Inclusion and Exclusion Criteria', 'Demographics and Baseline Characteristics', 'Medical History', 'Disease History', 'Medication History', 'Laboratory values', 'Demographics will be summarized using descriptive statistics, by treatment group and site.', '10.4.5 INTERIM ANALYSES', 'Not applicable for a pilot study of this nature. Safety findings that may prompt temporary suspension of enrollment and', 'safety review are discussed in section 8.1.', '10.4.6 SUB-GROUP ANALYSES', 'Not applicable for a pilot study of this nature', '10.4.7 MISSING DATA AND OUTLIERS', 'We will perform imputation for the anticipated small number of missing outcomes, but as is now becoming commonly', 'known, we expect the impact of such imputation to be minor. The imputation may be slightly different for different', 'outcomes. For a given outcome, missing data from a visit missed that is flanked by available visits may allow for', '35']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'averaging and multiple imputation based on the average of the flanking values. The utility of this approach will', 'necessarily depend on the type of missing data and the pattern of the flanking values. In cases where imputation is', 'deemed appropriate, PROC MI/PROC MIANALYZE (SAS Institute Inc., Cary, NC) will be used. We will generate five', 'replicates of the event or outcome of interest and redo the assessments. For secondary and exploratory outcomes, we', 'will use similar approaches. We will use propensity score matching (which reduces the cohort by any mismatches and', 'thus is different than covariate adjustment) to assess the impact of the missingness mechanism. We will examine the', 'sensitivity of the conclusions to any missingness found.', '11 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS', '11.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS', '11.1.1 INFORMED CONSENT PROCESS', '11.1.1.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS', 'Consent forms describing in detail the study intervention, study procedures, and risks will be given to the participant and', 'written documentation of informed consent is required prior to starting intervention/administering study intervention.', 'The following consent materials are submitted with this protocol.', '11.1.1.2 CONSENT PROCEDURES AND DOCUMENTATION', \"Informed consent is a process that is initiated prior to the individual's agreeing to participate in the study and continues\", \"throughout the individual's study participation. Participants will be asked to read and review the UAB IRB approved\", 'consent forms (see MOOP section 2.f). The investigator will explain the research study to the participant and answer any', \"questions that may arise. A verbal explanation will be provided in terms suited to the participant's comprehension of the\", 'purposes, procedures, and potential risks of the study and of their rights as research participants. Participants will have', 'the opportunity to carefully review the written consent form and ask questions prior to signing. The participants should', 'have the opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to', 'participate.', 'The participant will sign the informed consent document prior to any procedures being done specifically for the study.', 'Participants will be informed that participation is voluntary and that they may withdraw from the study at any time,', 'without prejudice. A copy of the informed consent document will be given to the participants for their records. The', 'informed consent process will be conducted and documented in the source document (including the date), and the form', 'signed, before the participant undergoes any study-specific procedures. The rights and welfare of the participants will be', 'protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to', 'participate in this study.', '11.1.2 STUDY DISCONTINUATION AND CLOSURE', 'This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written', 'notification, documenting the reason for study suspension or termination, will be provided by the suspending or', 'terminating party to study participants, investigator, NIAMS, and regulatory authorities. If the study is prematurely', 'terminated or suspended, the PI will promptly inform study participants, the IRBs, and NIAMS and will provide the', 'reason(s) for the termination or suspension. Study participants will be contacted, as applicable, and be informed of', 'changes to study visit schedule.', '36']\n\n###\n\n", "completion": "END"}